Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer

Staab, H. J.; Anderer, F. A.; Stumpf, E; Hornung, A.; Fischer, Rainer; Kleninger, Günther

doi:10.1016/s0002-9610(85)80064-7

Cited by 85 publications

(21 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A multicentre trial in the UK addressing this issue is nearing completion. Previous reports show that only about half the patients who undergo second-look surry have resectable disease, though the proportion who have further potentially curative surgery is higher in patients with asymptomatic recurrene detected by CEA; survival in the latter group is also improved (Minton et al, 1985;Staab et al, 1985;Quentmeier et al, 1990).…”

Section: Recurrent Diseasementioning

confidence: 98%

“…For single measurements (e.g. preoperative levels) it is possible to compare the specificity and sensitivity of two tests independently of the cut-off level used to define the abnormality by using receiver operating characteristic (ROC) curve analysis (Pasanen et al, 1993;Zweig & Campbell, 1993 (Beart & O'Connell, 1983;Hine & Dykes, 1984), some on a trend (Staab et al, 1985;Sugarbaker et al, 1987), and others using more complicated analytical methods (Martin et al, 1977). This issue was addressed specifically by Denstman et al (1986), but although some form of slope analysis was recommended in preference to an absolute cut-off value no firm guidein could be offered.…”

Section: Recurrent Diseasementioning

confidence: 99%

“…Many clinicians will include the measurement of CEA as an essential investigation in the detection of asymptomatic recurre of colorectal cancer. Those surgeons who advocate the use of second-look surgery advise that CEA should be measured every 6-8 weeks so that a suspicious rising level can be identified as early as possible (Staab et al, 1985;Minton & Chevinsky, 1989); for others 3 monthly CEA testing during the high-risk period of the first 2 years after resection tends to be the rule with a reduction in frequency of testing thereafter (Hine & Dykes, 1984).…”

mentioning

confidence: 99%

See 2 more Smart Citations

The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer

Hall

Finan²,

Stephenson³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

show abstract

Section: Recurrent Diseasementioning

confidence: 98%

Section: Recurrent Diseasementioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer

Hall

Finan²,

Stephenson³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Carcinoembryonic antigen (CEA) is the best known and most widely used of the markers (Minton et al, 1985;Staab et al, 1985;Wanebo et al, 1989), but in recent years the production of monoclonal antibodies against colorectal cancer-associated mucin antigens have allowed the detection of a further series of markers. These include CA 19-9, CA-50, (Hammarstrom, 1985;Gupta et al, 1987;Safi et al, 1987;Sagar et al, 1991;Nilsson et al, 1992).…”

mentioning

confidence: 99%

The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer

Ward

Primrose²,

Finan³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

Summary Tumour markers CEA, were measured in 33 patients undergoing chemotherapy for advanced colorectal cancer. The aim was to determine whether they could be used to accurately monitor the course of the disease, and reduce the need for imaging. Treatment with a 5-fluorouracil based regimen resulted in a partial response in nine patients (27%), whereas the remainder either had disease stabilisation or suffered from progression. Before treatment the CEA was elevated in 85% of patients and the and CA-242 in 78%. All three markers were elevated in 70% and at least one elevated in 93%. (Hammarstrom, 1985;Gupta et al., 1987;Safi et al., 1987;Sagar et al., 1991;Nilsson et al., 1992). Although none of these markers has proved to be of any particular value in screening for the disease, CEA is commonly used to assess the progress of patients following surgical treatment (Minton et al., 1985) and remains the 'gold standard'. Other markers appear less useful in isolation, but when combined as a panel with CEA may be of greater value than any one marker on its own (Safi et al., 1987;Persson et al., 1989). The aim of this study was to assess whether three tumour markers CEA, are of value in monitoring the progress of patients being treated with systemic chemotherapy for advanced colorectal cancer. Patients and methods PatientsThirty-three patients were studied; 24 were male and nine female, mean ages 58 (range 27-76) and 60 (42-78) respectively. All patients had histologically proven colorectal cancer with metastases. Twenty-six had liver metastases, ten locoregional disease, eight lung metastases, and two with disease at other sites. Several of these patients had disease at more than one site. The patients were a consecutive series in chemotherapy studies which required that the disease was measurable on CT scan. The time interval between presentation with the primary tumour and recurrent disease averaged at 16 months with a range of 0-91 months. Performance status was assessed by means of the Karnofsky scale (Karnofsky et al., 1948), the average being 80 with a range of 70-90.The study was approved by Leeds Eastern District Clinical Research (Ethics) Committee.Treatment schedule All patients received chemotherapy with a 5-fluorouracil (5-FU) based regimen as detailed below. Some of these patients were being treated in a multi-centre study comparing 5-FU and interferon alpha with 5-FU and leucovorin. The results of this study will be published separately. In the 5-FU/ interferon based regimen 5-FU was administered as a continuous intravenous infusion over a period of 5 days at a daily dose of 750 mg m2 followed by weekly intravenous bolus doses also of 750 mg m-2 commencing on day fifteen. Interferon alpha-2a 9 MU, was administered as a subcutaneous injection three times weekly. In the 5-FU/ leucovorin based regimen I-leucovorin 200 mg m-2 was infused over 10 min and followed within 5 min by a bolus of 5-FU at 370 mg m-2 for 5 consecutive days. This cycle was repeated every 4 weeks. Tumour markersA 10 ml sample of ...

show abstract

“…If serum CEA is elevated before treatment, the value falls to normal within one month following successful therapy. For these patients CEA is important for detection of recurrence at an early stage (9)(10)(11)(12)(13)(14)(15).…”

mentioning

confidence: 99%

Carcinoembryonic Antigen in Anal Carcinoma

1992

View full text Add to dashboard Cite

Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer

Cited by 85 publications

References 15 publications

The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer

The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer

The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer

Carcinoembryonic Antigen in Anal Carcinoma

Contact Info

Product

Resources

About